Zai Lab Limited (HKG:9688)
21.48
+0.52 (2.48%)
Nov 10, 2026, 4:08 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $108.21M USD in the quarter ending September 30, 2026, a decrease of -6.79%. This brings the company's total for the last twelve months to $441.73M, up 0.02% year-over-year. In the year 2025, Zai Lab had annual revenue of $460.16M with 15.33% growth. That makes Zai Lab the 11,998th largest company in the world by revenue and 715th in Hong Kong.
Revenue (ttm)
$441.73M
Revenue Growth
+0.02%
P/S Ratio
6.83
Revenue / Employee
$247.60K
Employees
1,784
Market Cap
23.68B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 460.16M | 61.17M | 15.33% |
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
| Dec 31, 2018 | 129.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 20.63B |
| Shanghai Henlius Biotech | 8.58B |
| InnoCare Pharma | 3.93B |
| Shanghai Junshi Biosciences | 3.75B |
| Everest Medicines | 2.78B |
| Biocytogen Pharmaceuticals (Beijing) | 2.15B |
| InSilico Medicine Cayman TopCo | 1.06B |
| Duality Biotherapeutics | 972.22M |
Zai Lab News
- 18 hours ago - Consensus Price Target for Zai Lab Limited - Depositary Receipt Increased by 12.10% to $31.30 - Nasdaq
- 3 days ago - Zai Lab Q3 Earnings Call Highlights - MarketBeat
- 4 days ago - Zai Lab (ZLAB) Q3 2026 Earnings Call Transcript - The Motley Fool
- 4 days ago - Zai Lab presents updated clinical data on zocilurtatug pelitecan - TheFly
- 4 days ago - Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas - Business Wire
- 4 days ago - Zai Lab Earnings Call Transcript: Q3 2026 - Transcripts
- 4 days ago - Zai Lab Earnings release: Q3 2026 - Filings
- 4 days ago - Zai Lab Quarterly report: Q3 2026 - Filings